Merck Is Top DJIA Stock in 2015
Merck shares posted a new 52-week high last Tuesday and closed Friday less than a buck from that high. Year to date, Its shares are up 11%.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 274Has eHealth Fallen Too Far?
eHealth was devastated in Thursday’s trading as the company announced its preliminary results for its fourth quarter.
Did Ziopharm and Intrexon Run Too Much on an MD Anderson Pact?
When two stocks run up over 50% and 30% on the same news, investors have to wonder if the move in the stock was justified or if the news-pop was due to trading factors…
Short Interest in Biotechs Signals Optimism
24/7 Wall St. has reviewed the short interest in the top biotech companies, without focusing on speculative companies.
Celgene Expects to More Than Triple Earnings by 2020
Celgene Corp. provided a preliminary look at its financials for 2014 but also gave its financial outlook for 2015 and far beyond at the Annual J.P. Morgan Healthcare Conference.
Is the Merger a Great Deal for Tekmira Shareholders?
Tekmira Pharmaceuticals and OnCore Biopharma have announced that they will merge to form a new company to develop a curative regimen for hepatitis B patients.
Has Agenus Run Too Much?
Agenus, in conjunction with Incyte, announced a global license for the development and commercialization of Agenus's proprietary Retrocyte Display antibody discovery platform.
The Bullish and Bearish Case for UnitedHealth in 2015
As the nation's largest health insurance provider, UnitedHealth is often front and center in the fight or review of the Affordable Care Act.
The Bullish and Bearish Case for Pfizer in 2015
One key consideration for the year ahead is that the Pfizer of 2016 or 2017 is likely to be night and day different from the Pfizer of 2005.
Gilead Continues to Recover from Express Scripts Loss
Gilead Sciences was picked up by Anthem to provide its hepatitis C drug as the primary option for patients.
Analyst’s Top 3 Biotech Picks for 2015 With Upside and Takeover Potential
A recent research piece from the biotech analysts at Stifel focused on three top stocks to buy with outstanding potential.
The Bullish and Bearish Case for Merck in 2015
One key consideration for the year ahead is Merck's acquisitions of Idenix and Cubist Pharmaceuticals to expand its product offerings
6 Serious Biotech and Health Care Movers
In Thursday morning’s trading session, it seemed almost across the board that biotech stocks were the largest gainers.
GW Cannabinoid Drug Fails Cancer Pain Trial
GW Pharmaceuticals reported top-line results from the first of three Phase 3 trials for Sativex.
Wells Fargo’s Top Biotech Stocks for 2015
ThinkstockLooking back at 2014, biotechs had a phenomenal year, and this looks to continue into 2015. The NYSE Arca Biotech index was up over 45% for 2014, and Wells Fargo expects that the biotech…